LevelJump Announces Q3 2024 Financial Results; Provides Update on Cease Trade Order
LevelJump Healthcare reported its Q3 2024 financial results, showing significant improvement. Q3 revenues reached $4.45 million, up 57% year-over-year, with gross profit of $880,194. The quarterly net loss narrowed to $(18,960) from $(1,668,916) in 2023, while EBITDA was $704,834. For the first nine months of 2024, revenues totaled $12.9 million with EBITDA of $1,365,030. The company opened a new location at Yonge Sheppard in September and is currently working to resolve a Cease Trade Order with the OSC to reinstate trading on TSX Venture Exchange.
LevelJump Healthcare ha pubblicato i risultati finanziari del terzo trimestre 2024, mostrando un miglioramento significativo. I ricavi del Q3 hanno raggiunto 4,45 milioni di dollari, con un aumento del 57% rispetto all'anno precedente, e un profitto lordo di 880.194 dollari. La perdita netta trimestrale si è ridotta a $(18.960) da $(1.668.916) nel 2023, mentre l'EBITDA è stato di 704.834 dollari. Per i primi nove mesi del 2024, i ricavi totali sono stati di 12,9 milioni di dollari con un EBITDA di 1.365.030 dollari. L'azienda ha aperto una nuova sede a Yonge Sheppard a settembre e sta attualmente lavorando per risolvere un ordine di cessazione della negoziazione con l'OSC per ripristinare il commercio presso la Borsa TSX Venture.
LevelJump Healthcare reportó sus resultados financieros del tercer trimestre de 2024, mostrando una mejora significativa. Los ingresos del Q3 alcanzaron 4,45 millones de dólares, un incremento del 57% interanual, con una utilidad bruta de 880.194 dólares. La pérdida neta trimestral se redujo a $(18.960) desde $(1.668.916) en 2023, mientras que el EBITDA fue de 704.834 dólares. Durante los primeros nueve meses de 2024, los ingresos totalizaron 12,9 millones de dólares con un EBITDA de 1.365.030 dólares. La compañía abrió una nueva ubicación en Yonge Sheppard en septiembre y actualmente está trabajando para resolver una orden de cese de operaciones con la OSC para reinstaurar el comercio en la Bolsa de Valores TSX Venture.
LevelJump Healthcare는 2024년 3분기 재무 결과를 발표하며 상당한 개선을 보여주었습니다. 3분기 수익은 445만 달러에 도달해 전년 대비 57% 증가했으며, 총 이익은 880,194달러였습니다. 분기 순손실은 2023년의 $(1,668,916)에서 $(18,960)으로 축소되었고, EBITDA는 704,834달러였습니다. 2024년 첫 9개월 동안 수익은 총 1,290만 달러로, EBITDA는 1,365,030달러에 달했습니다. 회사는 9월에 Yonge Sheppard에 새로운 지점을 열었으며, 현재 TSX 벤처 거래소에서 거래를 재개하기 위해 OSC와의 거래 중지 명령을 해결하기 위해 작업하고 있습니다.
LevelJump Healthcare a publié ses résultats financiers du 3ème trimestre 2024, montrant une amélioration significative. Les revenus du T3 ont atteint 4,45 millions de dollars, en hausse de 57 % d'une année sur l'autre, avec un bénéfice brut de 880.194 dollars. La perte nette trimestrielle s'est réduite à $(18.960) contre $(1.668.916) en 2023, tandis que l'EBITDA était de 704.834 dollars. Pour les neuf premiers mois de 2024, les revenus se sont élevés à 12,9 millions de dollars avec un EBITDA de 1.365.030 dollars. L'entreprise a ouvert un nouveau site à Yonge Sheppard en septembre et travaille actuellement à résoudre un ordre de cessation de négociation avec l'OSC pour rétablir le commerce sur la Bourse de TSX Venture.
LevelJump Healthcare hat seine Finanzresultate für das 3. Quartal 2024 veröffentlicht und zeigt eine deutliche Verbesserung. Die Einnahmen im Q3 beliefen sich auf 4,45 Millionen Dollar, was einem Anstieg von 57 % im Vergleich zum Vorjahr entspricht, mit einem Bruttogewinn von 880.194 Dollar. Der quartalsmäßige Nettverlust verringerte sich auf $(18.960) von $(1.668.916) im Jahr 2023, während das EBITDA 704.834 Dollar betrug. In den ersten neun Monaten des Jahres 2024 beliefen sich die Einnahmen auf insgesamt 12,9 Millionen Dollar bei einem EBITDA von 1.365.030 Dollar. Das Unternehmen eröffnete im September einen neuen Standort in Yonge Sheppard und arbeitet derzeit an der Lösung einer Handelsstoppverfügung mit der OSC, um den Handel an der TSX Venture Exchange wiederherzustellen.
- Revenue growth of 57% YoY in Q3 2024
- Significant reduction in net loss from $(1.67M) to $(19K) YoY
- Strong Q3 EBITDA of $704,834
- Annual revenue run rate exceeding $17 million
- Expansion with new Yonge Sheppard location
- Ongoing Cease Trade Order affecting stock trading
- Still operating at a net loss of $(749,839) for first 9 months
- Pending regulatory compliance issues with OSC
Toronto, Ontario--(Newsfile Corp. - December 2, 2024) - LevelJump Healthcare Corp. (TSXV: JUMP) ("LevelJump" or the "Company"), announced today its financial results for the quarter ended September 30, 2024.
Q3 Financial and Operational Highlights
- Revenues from operations were
$4.45 million in the third quarter an increase of57% compared to the third quarter of 2023.
- Gross profit from operations was
$880,194 in the third quarter.
- Consolidated net loss in the third quarter of 2024 was
$(18,960) compared to a loss of$(1,668,916) in 2023. - EBITDA in the third quarter was
$704,834.
2024 Nine Month Financial Results for LevelJump
- Revenues of
$12.9 million in the first 9 months - Year to date consolidated net loss of
$(749,839) , compared to a net loss of$(2,117,250) in the same period of 2023.
- Year to date EBITDA of
$1,365,030.
- EBITDA for the first nine months of 2024, per share of
$0.01 4.
Management Comments
"The third quarter was quite strong, and we are now tracking over
Update on Cease Trade Order
Further to its new release of September 3, 2024, the Company advises that its application to revoke the FFCTO continues to be processed by the OSC. The Company has responded to an initial set of comments and is working diligently to reply to a secondary set of comments which includes finalizing the presentation of the 3rd quarter financial statements. The Company is hopeful that it will be able to resolve all issues in the very near future and to commence the process to reinstate trading of the Company's shares on the TSX Venture Exchange.
Non-IFRS Financial Measures
This news release contains financial terms (such as adjusted EBITDA) that are not considered in IFRS. Such financial measures, together with measures prepared in accordance with IFRS, provide useful information to investors and shareholders, as management uses them to evaluate the operating performance of the Company. The Company's determination of these non-IFRS measures may differ from other reporting issuers, and therefore are unlikely to be comparable to similar measures presented by other companies. Further, these non-IFRS measures should not be considered in isolation or as a substitute for measures of performance or cash flows prepared in accordance with IFRS. These financial measures are included because management uses this information to analyze operating performance and liquidity.
About LevelJump Healthcare
LevelJump Healthcare Corp., (TSXV: JUMP) provides telehealth solutions to client hospitals and imaging centers through its Teleradiology division, as well as in person radiology services through its Diagnostic Centres. JUMP focuses primarily on critical care for urgent and emergency patients, establishing integral relationships in the communities we serve.
ON BEHALF OF THE BOARD OF DIRECTORS OF
LEVELJUMP HEALTHCARE CORP.
Mitchell Geisler
Chief Executive Officer
info@leveljumphealthcare.com
647-340-2020
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING INFORMATION
This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the Company's business plans and the outlook of the Company's industry. Although the Company believes, in light of the experience of its officers and directors, current conditions and expected future developments and other factors that have been considered appropriate, that the expectations reflected in this forward-looking information are reasonable, undue reliance should not be placed on them because the Company can give no assurance that they will prove to be correct. Actual results and developments may differ materially from those contemplated by these statements. The statements in this press release are made as of the date of this release and the Company assumes no responsibility to update them or revise them to reflect new events or circumstances other than as required by applicable securities laws. The Company undertakes no obligation to comment on analyses, expectations or statements made by third-parties in respect of the Company, Canadian Teleradiology Services, Inc., their securities, or their respective financial or operating results (as applicable).
Neither the Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Exchange) accepts responsibility for the adequacy or accuracy of this release.
The securities being offered have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any U.S. state securities laws, and may not be offered or sold in the United States or to, or for the account or benefit of, United States persons absent registration or an applicable exemption from the registration requirements of the U.S. Securities Act and applicable U.S. state securities laws. This press release does not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor in any other jurisdiction.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/232109
FAQ
What was LevelJump's (JMPHF) revenue growth in Q3 2024?
How much did LevelJump (JMPHF) reduce its net loss in Q3 2024?
What is the status of LevelJump's (JMPHF) Cease Trade Order in December 2024?
What was LevelJump's (JMPHF) EBITDA for the first nine months of 2024?
